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Tetracycline-regulated vectors were used to obtain inducible expression in stable transfected B cell lines of two Epstein–
Barr virus (EBV) latent genes, LMP1 and EBNA2. The transfected genes were tightly repressed by low, nontoxic concentra-
tions of tetracycline (£1 mg/ml) and, following removal of tetracycline, were induced to levels comparable to or up to 31
that of EBV-transformed normal lymphoblastoid cell lines. In transfected DG75 cells, induced expression of LMP1, but not
of EBNA2, led to the expected upregulation of various cell surface markers, including: CD40, CD54, CD58, and HLA class
I. A novel observation was that both LMP1 and EBNA2 independently caused the downregulation of surface IgM, an effect
mirrored in EBV-positive Burkitt lymphoma lines undergoing phenotypic drift during the transition from latency I to latency
III in which both LMP1 and EBNA2 are upregulated. Most remarkably, induced LMP1 expression almost completely inhibited
cell growth for 4 to 5 days, after which the cells recovered a limited proliferative capacity. The cytostatic effect of LMP1
was observed in all three B cell lines studied: DG75, BJAB, and Akata. Further analysis showed that induction of LMP1
coincided with a reduction in the levels of c-myc, and that the cytostatic effect was due to an accumulation of cells at the
G2/M phase of the cell cycle. These data suggest a novel function for the LMP1 oncogene in controlling the proliferation
of EBV-infected cells by regulating progress through G2/M phase. q 1996 Academic Press, Inc.
INTRODUCTION and there is also evidence of synergy with EBNA2 in
upregulating certain cellular proteins (Rowe, 1995; Wang
Epstein–Barr virus (EBV) is a remarkably efficient
et al., 1990a). Consistent with its role in cell transforma-
transforming agent for human B lymphocytes. Infection
tion, LMP1 has been shown to modulate expression ofof resting B cells in vitro regularly results in the establish-
several cell surface receptors, including CD21 (C3d/EBVment of EBV-carrying lymphoblastoid cell lines (LCL) in
receptor), CD23 (low-affinity IgE receptor, FceRII), CD40which only a limited set of so-called latent viral genes
(member of the TNFR superfamily), and EGF-receptor,are expressed, including six nuclear proteins (EBNA1, 2,
that are mediators of signalling events affecting cellular3A, 3B, 3C, and -LP) and two membrane proteins (LMP1
activation or proliferation (Huen et al., 1995; Miller et al.,and LMP2). Genetic analysis has shown that the immor-
1995; Peng and Lundgren, 1992; Wang et al., 1988; Wangtalization of primary B cells by EBV requires the coopera-
et al., 1990a). LMP1 also enhances cell survival, probablytive functions of at least five of the latent proteins (Cohen
through upregulation of Bcl-2 and/or the A20 antiapop-et al., 1989; Hammerschmidt and Sugden, 1989; Robert-
totic proteins (Henderson et al., 1991; Laherty et al., 1992;son and Kieff, 1995). The EBNA2 gene was the first to
Miller et al., 1995; Rowe et al., 1994). Paradoxically, ge-be identified as essential for B cell transformation by
netic studies with mutant LMP1 genes suggest that com-EBV, and subsequently EBNA3A, EBNA3C, and LMP1
petence for transformation correlates with toxicity (Ham-were also found to be indispensable. EBNA-LP, while
merschmidt et al., 1989; Martin et al., 1993), and othernot essential, has a marked effect upon the efficiency of
studies suggest that LMP1 may impair cell growth whentransformation. The LMP1 gene is of particular interest
introduced into B cell lines (Cuomo et al., 1992; Torsteins-because it is a classical oncogene, as defined by its
dottir et al., 1989).ability to transform rodent fibroblast lines and render
Most of our knowledge of the effects of LMP1 uponthem tumorigenic (Baichwal and Sugden, 1988; Wang et
cellular phenotype has been gained from gene transfec-al., 1985). Furthermore, LMP1 has pleiotropic effects
tion studies. Frequently this has involved comparison ofwhen expressed in cells that are natural targets for EBV
clones of cell lines constitutively expressing transfectedinfection, i.e., human lymphocytes and epithelial cells,
LMP1 genes with control clones transfected with vector
DNA only. This approach has been criticized on the
1 Institute for Cancer Studies, University of Birmingham Medical grounds that it could lead to the outgrowth of unrepresen-School, Vincent Drive, Birmingham, B15 2TJ, UK.
tative LMP1-positive clones which have acquired sec-2 To whom correspondence and reprint requests should be ad-
dressed. Fax: /44 (0) 1222 745003. E-mail: Rowem@cf.ac.uk. ondary genetic characteristics that provide a growth or
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survival advantage to counteract the postulated toxic BL (Mene´zes et al., 1975). Akata is an EBV-positive BL
cell line that displays a latency I type of EBV infectionproperties of LMP1. To some extent this problem can be
overcome by the use of transient expression assays in typical of the original biopsy cells of EBV-positive BL
tumours, in which the only viral protein expressed iswhich the target cells are transfected with an LMP1 ex-
pression vector and the assays for LMP1-induced effects EBNA1 (Rowe et al., 1992). Mutu-I and BL72-I likewise
are both EBV-positive BL cell lines that have retained aperformed within 12–48 hr (Huen et al., 1995; Martin et
al., 1993; Peng and Lundgren, 1992, 1993; Rowe et al., latency I form of infection, while Mutu-III and BL72-III are
subclones of these same lines that have drifted to the1994). However, this transient transfection strategy is of
limited use when trying to study the effects of LMP1 upon latency III type of infection in which all six EBNAs and
both LMP1 and LMP2 are expressed (Gregory et al.,cell growth. An alternative approach involves generation
of stable transfectants in which LMP1 expression is regu- 1990; Rowe et al., 1985). IARC307 is a spontaneous EBV-
transformed normal LCL derived from the same patientlated by an inducible promoter so that the clones can be
established in the absence of LMP1, and expression of as BL72. All cells were cultured in bicarbonate-buffered
RPMI-1640 medium supplemented with 10% bovine fetalthe transfected gene can be induced in a controlled man-
ner in every cell of the culture. Limited success has been calf serum and antibiotics (200 U/ml penicillin and 200
mg/ml streptomycin) and were grown at 377 in a humidi-achieved through the use of a vector in which LMP1
expression is regulated by a metallothionein promoter fied atmosphere containing 5% CO2 .
(Cuomo et al., 1992; Rowe et al., 1994; Wang et al., 1990a).
Construction of tetracycline regulatable LMP1 andUnfortunately, regulation by the metallothionein promoter
EBNA2 expression vectorshas serious limitations: first, induction requires the use
of toxic heavy metal ions such as zinc or cadmium and,
The tTA-expressing plasmid, pUHD15-1, and the re-
second, there is frequently an unacceptably high level of
sponsive plasmid, pUHD10-3, were described previously
‘‘basal’’ LMP1 expression in the absence of heavy metal
(Gossen and Bujard, 1992). A hygromycin resistance
salts.
gene under the control of an SV40 promoter was cloned
In the present work we adapted the tetracycline-regu-
as a BamHI fragment into the unique BamHI site of
latable expression system of Gossen and Bujard (1992),
pUHD15-1 to create the drug-selectable tTA-expressing
in which the gene of interest is cloned downstream of a
vector, pJEF-3. A neomycin resistance gene under the
promoter containing binding sites for a hybrid tetracy-
control of an SV40 promoter was cloned as a blunt-end
cline-regulated transactivator (tTA) that is constitutively
BamHI fragment into a blunt-end unique XhoI site up-
expressed from a second cotransfected plasmid DNA.
stream of the tTA-responsive promoter of pUHD10-3 to
Tetracycline binds to the tTA and prevents binding to
create the responsive vector pJEF-4. An LMP1 cDNA was
the promoter which remains silent, but upon removal of
excised from pSG-LMP1 (Liebowitz et al., 1992) as an
tetracycline the tTA binds to the promoter sequences
EcoRI fragment and ligated into the unique EcoRI site in
and activates transcription. We used this inducible ex-
the multiple cloning site of pJEF-4 to produce pJEF-6. The
pression system to study the effects of LMP1 expression
EBNA2 open reading frame with a 5* rabbit b-globin
on cell growth. For comparison, we also expressed
intron was excised from the pSVEB1NA2 expression vec-
EBNA2 in the same system since this viral protein is also
tor (Wang et al., 1990b) as a ClaI–XbaI fragment and
essential for the transformation of B cells by EBV and,
blunt-end ligated into the XbaI site of pJEF-4 to produce
similarly to LMP1, will induce phenotypic effects when
pJEF-31.
transfected alone into B cells but, unlike LMP1, is not
reported to have toxic properties (A˚man et al., 1990; Generation of stable cell clones with regulatable
Wang et al., 1987, 1990a). Our results demonstrate the LMP1 or EBNA2 expression
usefulness of the tetracycline-regulatable system for the
expression of EBV latent genes, and also show that in- Electroporation of 107 cells with 10 mg DNA in 0.5-ml
volumes of growth medium was carried out in cuvettesduced expression of LMP1 has a cytostatic effect on B
cell lines due to an accumulation of cells at the G2/M with a 4-mm gap between electrodes using a Bio-Rad
Genepulser apparatus set to a capacitance of 960 mF.phase of the cell cycle.
The optimum set voltage was dependent upon the cell
line; being 270 V for DG75 and BJAB, and 280 V for Akata.MATERIALS AND METHODS
The stable clones with tetracycline-regulatable expres-
Cell lines
sion of LMP1 or EBNA2 were generated by two consecu-
tive rounds of transfection and selection. The first roundDG75 is an EBV-negative BL line derived from a spo-
radic case of BL (Ben-Bassat et al., 1977) and BJAB is involved transfection with the pJEF-3 transactivator plas-
mid and selection of clones resistant to hygromycin atan EBV-negative B lymphoma line that shares many char-
acteristics with a typical BL except that it lacks the char- 500 mg/ml. Expression of the tTA from stably integrated
pJEF-3 was verified using a tTA-responsive luciferaseacteristic chromosome translocation that is a marker for
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reporter, pUHC13-3 (Gossen and Bujard, 1992). Samples 1 mg/ml tetracycline. Cell counts were performed daily
for up to 6 days. Cell death by necrosis was assessedof the stable clones were transfected with this reporter
DNA and then divided into replicate cultures with or with- by trypan blue exclusion, and cell death by apoptosis
was assessed by acridine orange staining of cells (Hen-out 1 mg/ml tetracycline. After 24 hr cells were harvested
and the luciferase activity was determined using a chemi- derson et al., 1991).
luminescence assay as described elsewhere (Huen et
Flow cytometric analysisal., 1995); clones with the highest luciferase activity in
the absence of tetracycline and the lowest activity in the The expression of various cell surface markers was
presence of tetracycline were chosen for a second round analyzed by flow cytometry as described previously
of transfection with the LMP1 (pJEF-6) or EBNA2 (pJEF- (Rowe et al., 1994). The monoclonal antibodies used in
31) responder plasmids. Selection of clones with stably these experiments included CD10 (55), CD40 (G28.5),
integrated pJEF-6 or pJEF-31 DNA was carried out by CD54 (RR/1), and CD58 (TS2/9), which have previously
culturing in the presence of G418 (2 mg/ml for DG75 and been used to characterize the cellular phenotype of BL
BJAB, or 1 mg/ml for Akata) together with 500 mg/ml cells (Wang et al., 1990a), as well as the BU1 monoclonal
hygromycin and 1.0 mg/ml tetracycline. Dual-transfected antibody reactive with human immunoglobulin m chains
clones that were used in these studies were chosen on (Binding Site Ltd., Birmingham, UK) and the Tu¨149 mono-
the basis of their inducible expression of LMP1 or clonal antibody reactive with HLA-class I B allele anti-
EBNA2. This was determined by washing the cells three gens (Uchanska-Ziegler et al., 1993).
times in phosphate-buffered saline (PBS) and reculturing
replicate aliquots with or without tetracycline in the Cell cycle analysis
growth medium. After 24 hr the cells were harvested
DNA profiles of cells were obtained by staining cellsand their LMP1 or EBNA2 expression was assessed by
with propidium iodide followed by flow cytometric analy-immunoblotting. Stock cultures of the stable clones were
sis. Aliquots of 106 cells were harvested by centrifuga-maintained in the continuous presence of hygromycin,
tion, washed in PBS, and fixed in 70% cold ethanol forG418, and tetracycline.
at least 30 min. Following two washes in PBS, the cells
Detection of LMP1 or EBNA2 by immunofluorescence were resuspended in PBS containing 2 U/ml DNAse-
free RNAse and 0.5 mg/ml propidium iodide and were
Cells were harvested, washed twice in PBS, and used
incubated at room temperature for 30 min before being
to prepare air-dried smears that subsequently were fixed
analyzed on an EPICS Profile II flow cytometer.
in methanol:acetone (1:1) at 0207 for 10 min. These fixed
Bromodeoxyuridine (BrdU) pulse–chase experiments
cells were incubated first either with the CS.1-4 anti-
were carried out by pulsing cells with 10 mg/ml BrdU for
LMP1 or with the PE2 anti-EBNA2 murine monoclonal
30 min. Aliquots of 3 1 106 cells were harvested after 6,
antibodies and then with FITC-conjugated goat antibod-
12, and 24 hr by centrifugation and were washed in PBS
ies to murine IgG, exactly as described elsewhere (Rowe
before fixing in cold 70% ethanol for at least 30 min. Cells
et al., 1992), before examining by epifluorescence on a
were pelleted and then incubated in 2 M hydrochloric
Nikon Optiphot microscope.
acid for 20 min at room temperature. Following two
washes in PBS, cells were incubated with a mouse anti-Detection of proteins by Western blotting
BrdU monoclonal antibody (Bu20a; Dako Ltd.) diluted
Cells were solubilized and separated by Laemmli dis- 1:10 with PBS containing 0.1% Tween and 10% normal
continuous SDS–PAGE before electroblotting onto nitro- goat serum. After an incubation on ice for 1 hr, cells were
cellulose filters for probing with CS.1-4 (anti-LMP1), PE2 washed twice in PBS and stained on ice for 1 hr with a
(anti-EBNA2), or 9E10 (anti-c-myc; Santa Cruz Biotechnol- FITC-conjugated goat anti-mouse IgG reagent (F0257;
ogy, CA) murine monoclonal antibodies, as described Sigma) diluted 1:50 in PBS/10% normal goat serum. Cells
previously (Rowe et al., 1987). Specifically bound antibod- were then washed twice and resuspended in PBS con-
ies were detected using rabbit anti-mouse IgG (Z259; taining 0.5 mg/ml propidium iodide and analyzed by flow
Dako) followed by 125I-protein A. The probed filters were cytometry.
then subjected either to autoradiography with photo-
graphic film or, for quantitation, to phosphorimaging on RESULTS
a Molecular Dynamics phosphorimager.
Inducible expression of LMP1 and EBNA2 in stable
transfectantsGrowth assays
The growth of cells induced to express LMP1 following As described under Materials and Methods, the trans-
activator expressing vector of Gossen and Bujard (1992)tetracycline removal was determined by resuspension of
replicate aliquots of washed cells at 1.5 to 2 1 105 cells/ was modified by insertion of a hygromycin-resistance
gene to give the pJEF-3 plasmid shown in Fig. 1A. Theml in tetracycline-free medium or in medium containing
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FIG. 1. Inducible expression of LMP1 and EBNA2 from the tetracycline-regulated system in stable-transfected B cell lines. (A) The tetracycline-
regulated transactivator (tTA) is derived from a fusion of two genes (tetR and VP16 transactivator) and is constitutively expressed from a CMV/IE
promoter on the pJEF-3 plasmid. Expression of LMP1 from the responder plasmid pJEF-6 and EBNA2 from the responder plasmid pJEF-31 requires
binding of the tTA to a 5* regulatory region containing a minimal promoter. (B) The cell lines DG75-LMP1, BJAB-LMP1, and Akata-LMP1 were dual
transfected with pJEF-3 and pJEF-6 and stable integration was selected by growth in medium containing hygromycin-B, G418, and tetracycline.
Cultures of these stable lines were grown for 48 hr in the presence (/) or absence (0) of 1 mg/ml tetracycline before harvesting and analyzing
LMP1 expression by Western blotting with the CS1-4 monoclonal antibodies; for reference, the EBV-transformed LCL, X50-7, and the EBV-negative
BJAB parental line were run in parallel. The DG75-EBNA2 transfectant, in which pJEF-3 and pJEF-31 were stably integrated, was similarly cultured
in the presence or absence of tetracycline and then analyzed by Western blot for EBNA2 expression using the PE2 monoclonal antibody.
responder vector was also modified by the insertion of Two EBV-negative B cell lines (DG75, BJAB) and one
EBV-positive line (Akata) were transfected with the pJEF-a neomycin-resistance gene, and into this new vector
(pJEF-4) was inserted either the LMP1 gene to give the 3 transactivator plasmid, and stable clones were se-
lected in hygromycin-containing medium. Stable expres-pJEF-6 responder plasmid or the EBNA2 gene to give the
pJEF-31 responder plasmid (Fig. 1A). sion of tTA was confirmed by transient transfection
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assays with the tTA-responsive luciferase reporter,
pUHC13-3. Clones DG75-tTA, BJAB-tTA, and Akata-tTA,
which demonstrated the highest luciferase activity in the
absence of tetracycline but which showed only back-
ground luciferase activity when grown in the presence
of tetracycline, were chosen for a second round of trans-
fection with the responder plasmids. Cells transfected
with the pJEF-6 or pJEF-31 responder plasmids were se-
lected in the presence of G418 and were maintained
from the outset in medium containing 1 mg/ml tetracy-
cline. Clones for further study were then selected on
the basis of their inducible gene expression following
removal of tetracycline for 24 hr. As shown by the West-
ern blots in Fig. 1B, in the presence of tetracycline LMP1
or EBNA2 in the respective transfectants were barely
detectable, which suggests a tight regulation of tran-
scription with a low level of leakiness from the respon-
sive promoter. Removal of tetracycline in cultures of
Akata-LMP1, BJAB-LMP1, and DG75-LMP1 led to the ex-
pression of LMP1 at higher levels than seen in the X50-
7 reference LCL. Similarly, expression of EBNA2 was
induced to high levels in cultures of the DG75-EBNA2
transfectant following removal of tetracycline (Fig. 1B).
Time-course experiments were performed to deter-
mine the kinetics of the release of transcriptional repres-
sion following tetracycline removal. As illustrated by the
DG75-LMP1 line in Fig. 2A, induced expression of LMP1
was detected at 6–12 hr after washing the cells and
reculturing in tetracycline-free medium. The maximum
levels of LMP1 were typically two- to threefold higher
than that observed in the reference LCL and were
achieved within 24 hr of tetracycline removal. Readdition
of tetracycline to the DG75-LMP1 line expressing LMP1
led to a comparatively rapid decrease in LMP1 protein
levels (Fig. 2B). Indeed, the observed rate of LMP1 disap-
pearance was comparable to the half-life of the protein,
previously determined from metabolic labeling experi-
ments to be in the region of 3 to 5 hr (Baichwal and
Sugden, 1987; Mann and Thorley-Lawson, 1987), sug-
FIG. 2. Kinetics of induction and repression of LMP1 expression ingesting that the tetracycline-mediated repression is both
DG75-LMP1 cells. (A) DG75-LMP1 cells maintained in 1 mg/ml tetracy-efficient and rapid. The kinetics of EBNA2 induction fol-
cline (/ tet control) were washed and recultured in tetracycline-free
lowing tetracycline removal from the DG75-EBNA2 line medium for 3, 6, 12, 24, 48, or 72 hr before harvesting and analyzing for
were similar to those observed for LMP1 in Fig. 2A but, LMP1 expression by Western blot analysis using the CS.1-4 monoclonal
antibodies. As described in the legend of Fig. 1, the reference X50-7in contrast to the LMP1 transfectant, readdition of tetracy-
and BJAB lines were included in the analysis. The upper panel showscline to DG75-EBNA2 caused only a gradual fall of
an autoradiograph of the Western blot, and the lower panel shows aEBNA2 protein levels (data not shown) consistent with
histogram of the relative levels of LMP1 expression determined from
its known long half-life in excess of 24 hr (Grasser et al., a separate exposure of the same blot to a phosphorimaging system.
1991). (B) Tetracycline was removed from the DG75-LMP1 cells for 24 hr to
achieve high levels of LMP1 expression (0 tet control) before addingAnother potentially important property of the tTA-regu-
back tetracycline for periods of 2, 4, 6, 8, 10, or 24 hr. The results showlated expression system is the ability to regulate the level
an autoradiograph of a Western blot and quantitation by phosphorim-of gene expression in a dose-responsive fashion. As il-
aging, as in A.
lustrated in Fig. 3, it was necessary to reduce the concen-
tration of tetracycline below 4 ng/ml in order to allow
expression of LMP1 protein, and below this concentra- cence staining it was regularly observed that the interme-
diate levels of LMP1 expressed in the presence of 2 ng/tion the level of LMP1 correlated inversely with concen-
tration of the antibiotic. However, by immunofluores- ml tetracycline (Fig. 3) was largely due to the presence
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dium or were grown for 48 hr in tetracycline-free medium
prior to immunostaining with a panel of antibodies to CD10
(a neutral endopeptidase; EC 3.4.24.11), CD40 (a member
of the TNFR superfamily), CD54 (cellular adhesion molecule;
ICAM-1), CD58 (cellular adhesion molecule; LFA-3), IgM or
HLA class I. For reference, three well-characterized cell
lines were immunostained in parallel; a normal EBV-trans-
formed LCL, and two subclones of the EBV-positive Mutu
BL line which showed either a latency I pattern of viral gene
expression (EBNA1 only) or a latency III pattern of viral gene
expression (all six EBNAs, LMP1, and LMP2). Consistent
with earlier studies on conventionally transfected B cell
lines, induction of LMP1 in the DG75-LMP1 clone resulted
in upregulated expression of CD40, CD54, CD58, and HLA
class I, while induction of EBNA2 in the DG75-EBNA2 clone
had no effect upon expression of these markers. In the
case of CD40, CD54, and HLA class I, the expression was
increased to levels comparable to those on the Mutu-III BL
cells and on the LCL. The level of CD58 on DG75-LMP1
was upregulated nearly 10-fold following removal of tetracy-
cline, but this was still substantially less than that typically
observed on LCL. However, the induced level of CD58 on
FIG. 3. Tetracycline dose-response of LMP1 expression in the DG75-
the DG75-LMP1 line was comparable to that observed onLMP1 line. DG75-LMP1 cells were washed free of tetracycline and
the Mutu III reference line. Induction of LMP1 also causedthen reseeded in fresh medium containing tetracycline at 1 mg/ml, 4
ng/ml, 2 ng/ml, 1 ng/ml, 0.5 ng/ml, or in medium containing no tetracy- a four- to fivefold reduction in the levels of surface IgM,
cline. After 48 hr the cultures were harvested an analyzed by Western which is comparable to the difference observed in Mutu III
blotting as described in the legend of Fig. 2. cells relative to Mutu I cells. Interestingly, this effect was
also mediated by expression of EBNA2 (Fig. 4); this was
not an artifact of tetracycline removal since the DG75-tTAof 2–5% of the cells showing intense staining for LMP1
cells, i.e., with no responder plasmid, did not demonstratewhile the majority of the population showed little or no
this effect (data not shown). In previous studies LMP1, butdetectable staining. With reducing concentrations of tet-
not EBNA2, was reported to downregulate CD10 expressionracycline the percentage of brightly stained cells in-
in some cells (Wang et al., 1990a); here we found that induc-creased. In the absence of tetracycline the maximum
tion of LMP1 had only a small effect upon CD10, and thatlevel of LMP1 expression typically resulted in 75–85%
induction of EBNA2 likewise resulted in a slight downregula-cells with intense LMP1 staining but most of the re-
tion of this surface marker (Fig. 4). A phenotypic analysis ofmaining cells did show significant, albeit much weaker,
the BJAB-LMP1 transfectant demonstrated similar results tostaining for LMP1 (data not shown). Similar patterns of
those obtained with DG75-LMP1, but the Akata-LMP1 wasexpression were obtained with the EBNA2-transfected
found to be largely refractory to LMP1-mediated changesclone. These results suggest that the dose-respon-
in cell surface markers as previously observed in transientsiveness at the population level may largely be due to
transfection experiments (Rowe et al., 1994).different sensitivities of individual cells to what is essen-
tially an on-off switch. Therefore, in the present study we
Cytostatic effects of LMP1 in B cell lineschose to restrict the use of this system to a simple on-
off switch by the use of no tetracycline or tetracycline at
The growth characteristics of the transfected sublines1 mg/ml.
of DG75, BJAB, and Akata were studied by washing the
cells free of tetracycline and then reseeding replicateSurface phenotype changes following induction of
aliquots in medium either containing 1 mg/ml tetracyclineLMP1 or EBNA2
or lacking tetracycline. Viable cell numbers were quanti-
fied every 24 hr. As illustrated by a representative experi-Since LMP1 and EBNA2 are known to have pleiotropic
effects upon cellular phenotype, we first checked whether ment in Fig. 5A, control cultures reseeded in tetracycline
displayed exponential cell growth for 4 to 5 days. In con-such changes could be observed in our tTA transfectants
following induction of the relevant EBV protein. The flow trast LMP1-expressing transfectants reseeded in the ab-
sence of tetracycline showed no significant increase incytometry data in Fig. 4 show representative results from
one experiment in which DG75-LMP1 and DG75-EBNA2 cell number for at least 4 days. This growth inhibition
was shown to be a specific effect of LMP1 expressioncells were either maintained in tetracycline-containing me-
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FIG. 4. Effects of induced LMP1 or EBNA2 expression upon cell surface markers. DG75-LMP1 and DG75-EBNA2 cells were grown in the presence
(/) or absence (0) of tetracycline for 2 days before harvesting for indirect immunofluorescence staining for the cell surface markers indicated. The
murine monoclonal antibodies used were G28.5 (CD40), RR/1 (CD54), TS2/9 (CD58), Tu¨148 (HLA-B class I), BU1 (IgM), and 55 (CD10). Stained cells
were analyzed by flow cytometry, and the intensity of staining was quantitated as the mean fluorescence intensity (M.F.I.) on an arithmetic scale.
Reference group I (Mutu-I) and group III (Mutu-III) BL cell lines, together with a normal LCL, were included as control cells for the immunostaining
assays.
since comparison of DG75-LMP1 and DG75-EBNA2 factor determining the proliferative capacity of these
cells (Magrath et al., 1992). All three B cell lines (DG75,transfectants in parallel revealed that induction of EBNA2
expression by removal of tetracycline from the DG75- BJAB, Akata) that were used in this study have high
levels of c-myc protein consistent with their proliferativeEBNA2 line had no effect upon the growth kinetics (Fig.
5B). The LMP1-induced growth inhibition was a genuine capacity. We therefore quantitated the levels of c-myc
protein in the LMP1 transfectants at 48 hr after removalcytostatic effect since by microscopic observation there
was no obvious cell death occurring, rather the persis- of tetracycline. As shown in Fig. 7 for the DG75-LMP1
transfectant, the levels of c-myc were reduced by abouttence of viable growth-inhibited cells (Fig. 6). This was
quite different to the effects, for instance, of serum depri- 50% compared to the control cells maintained in tetracy-
cline. In order to determine whether or not this phenom-vation in BL cell cultures which leads to rapid apoptotic
cell death detected microscopically and by DNA staining enon could be observed in other translocation carrying
BL lines with ‘‘deregulated’’ c-myc expression, we com-(Gregory et al., 1991). Furthermore, the LMP1-induced
growth-impairment was fully reversible by readdition of pared the c-myc levels in paired group I and group III
sublines from the Mutu-BL and from BL72. The resultstetracycline at 50 hr after the first induction of LMP1.
Another reproducible feature of these experiments was (Fig. 7) showed that the phenotypic drift that accompan-
ies broadened EBV latent gene expression in these sub-that the cytostatic effect of LMP1 was temporary. Thus,
as clearly demonstrated in Fig. 5B, the cell numbers in lines is also accompanied by a marked decrease in c-
myc protein to levels typically observed in normal LCLs.the LMP1-expressing cells had increased on Days 5 and
6; upon refeeding the cultures and performing cell counts Significantly, a similar LMP1-associated decrease in c-
myc was also observed in the BJAB-LMP1 transfectantfor a further 6 days, those cultures in which LMP1 re-
mained expressed were observed to proliferate, albeit (data not shown) which does not possess a translocated
c-myc as do true BL lines.with a doubling time that was around twice as long as
the control LMP1-negative cultures (data not shown).
LMP1 leads to accumulation of cells at the G2/M
phase of the cell cycleInduced LMP1 expression results in downregulated
c-myc
Other studies in which growth arrest of BL cells has been
induced by a variety of agents (e.g., TGF-b, anti-m, or mutantBL lines display characteristic chromosome translo-
cations which disrupt the normal regulatory controls p53) suggest that antiproliferative effects commonly involve
accumulation of cells in the G1 phase of the cell cycleover c-myc gene, and this is thought to be a crucial
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chased in the continued presence of tetracycline. The profile
of BrdU-labeled LMP1-positive cultures at 6 hr was very
similar to the profile of control LMP1-negative cultures, sug-
gesting that the transition of S-phase-labeled cells into
G2/M was unimpaired. However, at 12 hr the profiles began
to show a significant difference, with fewer cells of the
LMP1-positive culture having completed mitosis and entered
G0/G1 . This was more pronounced after 24 hr when most
cells from the LMP1-positive culture remained in the
G2/M phase with only a small number having undergone
mitosis to accumulate in the G0/G1 compartment, while
in the control LMP1-negative cultures most cells were in
G0/G1 phase.
DISCUSSION
Because of the paradox that LMP1 has both oncogenic
and toxic properties, there was a need to develop more
FIG. 5. Growth kinetics of transfectants induced to expresss LMP1
or EBNA2. (A) Growth kinetics of Akata-LMP1 (l, s), BJAB-LMP1 (m,
n), and DG75-LMP1 (j, h) that were washed free of tetracycline then
reseeded at 2 1 105 cells/ml in fresh medium containing (closed sym-
bols) or lacking (open symbols) 1 mg/ml tetracycline. The (/) and (0)
symbols indicate the status of LMP1 expression in the transfectants.
Cells were counted daily for 5 days, and viability was assessed by
trypan blue exclusion. (B) A separate experiment performed as in A,
but comparing the growth kinetics of the DG75-LMP1 transfectant with
the DG75-EBNA2 transfectant. Cells were counted daily for 6 days.
(MacDonald et al., 1996; Okan et al., 1995). We therefore
investigated whether the cytostatic effect of LMP1-express-
ing transfectants was due to accumulation of cells at a
specific stage of the cell cycle. The DNA profiles obtained
by flow cytometric analysis of propidium iodide-stained cells
showed that DG75-LMP1 cells grown for 48 hr in the ab-
sence of tetracycline (i.e., LMP1-positive) contained almost
three times as many cells in the G2/M phase as control
cultures grown in the presence of tetracycline (Fig. 8). The
increase of cells in the G2/M phase was reflected by a
decrease of cells in both the S and the G0/G1 compartments
of the cell cycle. The accumulation of LMP1-expressing cells
in the G2/M phase was confirmed in further experiments
where the cultures were pulse-chased with BrdU (Fig. 9).
In the experiment illustrated, DG75-LMP1 cells were in-
duced to LMP1 positivity by tetracycline removal for 24 hr,
FIG. 6. Effects of LMP1 expression on cell viability of DG75-LMP1pulsed with BrdU for 30 min to label S-phase cells, washed,
cells. DG75-LMP1 cells were grown in the presence (A) or absenceand reseeded in tetracycline-free medium for a further 6,
(B) of tetracycline for 3 days before photography of the cultures. The
12, or 24 hr to chase the labeled cells before analyzing LMP1-postive cultures shown in B contained fewer cells than did the
the DNA profiles in propidium iodide-stained cells. Control LMP1-negative cultures shown in A, but there is no evidence of in-
creased cell death being responsible for the difference in cell density.parallel cultures of DG75-LMP1 cells were labeled and
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at which they respond to tetracycline in an essentially
on-off manner.
Routine screening of our new transfectants confirmed
previously documented effects of LMP1 upon CD40,
CD54, CD58, and HLA class I (Rowe et al., 1995, 1994;
Wang et al., 1990a) and also led to the novel observation
that LMP1 caused a fourfold downregulation of surface
IgM levels (Fig. 4). Interestingly, a similar downregula-
tion of IgM was also effected by EBNA2 in the DG75-
EBNA2 transfectant, but it is not known whether the
effect upon IgM is the result of a common signalling
event directly initiated both by LMP1 and by EBNA2.
The effect of LMP1 and EBNA2 upon IgM expression
in these transfected lines is relevant to the biological
properties of EBV since it mirrors the downregulation
of IgM that occurs during the drift of BL cells from a
latency I form of infection to a latency III form of infection
(see Mutu and BL72; Fig. 4).
The most striking effect of LMP1 demonstrated with
the tetracycline-regulated expression system was the cy-
tostatic effect. This phenomenon was not an artifact of
the tetracycline-regulated system, since induction of
EBNA2 had no effect upon growth (Fig. 5), and it was not
a consequence of the presumed toxicity of LMP1 that has
previously been reported (Hammerschmidt et al., 1989),
since there was no evidence of increased cell deathFIG. 7. Inverse correlation between c-myc levels and LMP1 expres-
sion. Protein extracts were prepared from various cell cultures and either via apoptosis or necrotic mechanisms (Fig. 6). Fur-
analyzed by Western blotting for for c-myc using the 9E10 murine mono- thermore, the LMP1-positive cells did eventually recover
clonal antibody and for LMP1 using the CS.1-4 antibodies. The probed
a proliferative capacity after 4 or 5 days, albeit they grewfilters were exposed to a phosphor screen and the intensity of the
more slowly than did the LMP1-negative control cells.specific bands quantitated on a phosphorimager. The relative levels
Other studies with conventional transfectants haveof c-myc (A) and LMP1 (B) are given in arbitrary units. The DG75-LMP1
cells were cultured for 48 hr in the presence (/) or absence (0) of shown that clones constitutively expressing LMP1 grow
tetracycline before harvesting. Other reference lines included: two more slowly than do control transfectants (Wang et al.,
group I subclones of the Mutu-BL (c59 and c179) and two group III
1988). Similarly, another study in which expression of asubclones of the Mutu-BL (c95 and c179); a group I subclone of the
transfected LMP1 gene under the control of metallothio-BL72 line (BL72 gpI), a group III subclone of the BL72 line (BL72 gpIII),
and a normal LCL from the BL72 patient (LCL).
appropriate inducible expression models in order to in-
vestigate further the functions of this protein. The present
results demonstrate that the tetracycline-regulatable ex-
pression system developed in epithelial cells by Gossen
and Bujard (1992) is suitable for obtaining tightly regu-
lated expression of EBV latent infection genes in B cell
lines. This system did not suffer the disadvantages of
metallothionein promoter constructs that were apparent
in previous studies on LMP1 function, where there was
usually significant basal expression of the regulated
gene and the induction required the addition of toxic
heavy metal salts (Cuomo et al., 1992; Rowe et al., 1994). FIG. 8. Effect of induced LMP1 expression upon cell cycle. DG75-
LMP1 cells were grown in the presence (A) or absence (B) of 1 mg/mlTheoretically, the tetracycline-regulated system might
tetracycline. After 48 hr the cell cycle distribution was determined byalso provide a way of regulating expression of exoge-
propidium iodide staining and flow cytometry for stained DNA content.nously transfected genes in a dose-responsive fashion;
The dotted lines indicate the observed DNA profile, while the shaded
however, the apparent dose-responsiveness at the popu- areas indicate the computer extrapolated distribution of the cells in
lation level most probably reflects variation among indi- the G0/G1, S, and G2/M phases of the cell cycle determined using
Coulter Cytologic Software.vidual cells with respect to the threshold concentration
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FIG. 9. BrdU pulse–chase experiment demonstrating the effect of induced LMP1 expression upon the progression of cells through cell cycle.
DG75-LMP1 cells were grown in the presence (A) or absence (B) of tetracycline for 24 hr before pulsing for 30 min with BrdU to label the DNA of
cells in S-phase. The labeled cells were then chased for 6, 12, or 24 hr before staining total DNA with propidium iodide and performing flow
cytometric analysis. The data illustrated show the DNA profiles of the BrdU-labeled cells only, and the percentages of cells in the different stages
of the cell cycle are indicated for each profile.
nein promoter was induced by addition of zinc salts 1992), it is clearly not completely insusceptible to reg-
ulation. Thus, the levels of c-myc in BL cells can beshowed that LMP1 slowed the rate of proliferation (Cu-
omo et al., 1990). This latter study is more comparable downregulated by cytokines such as interferon-a (Mil-
ner et al., 1995) and by several inducers of differentia-to the present work, yet its authors did not observe the
more severe cytostatic effect that we now report. This tion (Rottleb et al., 1995). In addition, other workers
have previously reported that infection of EBV-nega-may be due to the fact that the regulation of LMP1 ex-
pression from the metallothionein promoter is more leaky tive BL lines with EBV results in reduced c-myc (Tors-
teinsdottir et al., 1989), and we report here that thethan is observed with the tetracycline-regulated system;
therefore, the metallothionein-regulated LMP1-transfec- transition from a group I to a group III phenotype in
the EBV-positive Mutu and BL72 lines is accompaniedtants would have adapted to the low level of LMP1 that
was continuously expressed during the establishment of by a reduction in c-myc protein of similar magnitude
to that induced by LMP1 in DG75 cells (Fig. 7). Whilethe clones. The question remains as to the nature of the
partial recovery of BL cells from the initial cytostatic effect the LMP1-induced downregulation of both sIgM and c-
myc suggests the possibility of a common mechanismof LMP1. One possibility is that the plethora of phenotypic
effects of LMP1 includes stimulation of autocrine path- involving regulation via Ig enhancer elements because
of the BL-associated translocations whereby Ig en-ways that induce proliferation. If that is the case, then a
more detailed analysis of the Akata-LMP1 transfectants hancer elements and c-myc may be juxtaposed, this
is unlikely since the phenomenon was also observedproduced in the present work should prove informative
since this line is unusually refractory to many LMP1 func- when LMP1 was expressed in the BJAB lymphoma line
in which c-myc is presumed to be nontranslocated.tions (Rowe et al., 1994) and yet expression of LMP1
does have a cytostatic effect (Fig. 5). The mechanism of this effect requires further study,
particularly since we cannot ascertain from our pres-The cytostatic effect of LMP1 was found to be asso-
ciated with downregulated expression of c-myc and a ent data whether the downregulation of c-myc is a
cause or consequence of growth-impairment. How-partial block on cells leaving the G2/M phase of the
cell cycle. Although c-myc is aberrantly deregulated ever, it is interesting to note that decreased c-myc
expression can result in arrest of cells in the G2/Min BL lines as a result of the translocation of the c-
myc locus on chromosome 8 to the immunoglobulin phase of the cell cycle (Shibuya et al., 1992). It is
possible, therefore, that the LMP1-mediated accumu-locus on chromosome 14, 2, or 22 (Magrath et al.,
AID VY 8063 / 6a1c$$$$61 08-05-96 14:01:49 vira AP: Virology
39CYTOSTATIC EFFECT OF LMP1
lation of cells in G2/M may be a direct consequence aberrant c-myc expression and more responsive to auto-
crine growth stimulation.of an effect upon c-myc. Very recently, it was reported
that the HIV viral protein R arrests cells in the G2 phase
of the cell cycle by inhibiting p34cdc2 activity (He et al., ACKNOWLEDGMENTS
1995), but we have been unable to show any effect of
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